Transfusion-transmitted hepatitis B virus infection

Journal of Hepatology

Volumn 51, Issue 4, 2009, Pages 798-809

  Candotti, Daniel ^a   Allain, Jean Pierre ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Hepatitis B virus; Immunosuppression; Occult HBV infection; Transfusion; Transmission

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; MEMBRANE ANTIGEN; NEUTRALIZING ANTIBODY;

BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL OBSERVATION; DISEASE CARRIER; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HUMAN; IMMUNE DEFICIENCY; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; NONHUMAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEROCONVERSION; VIRUS LOAD; VIRUS NEUTRALIZATION;

BLOOD DONORS; BLOOD TRANSFUSION; CARRIER STATE; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; RISK FACTORS; TIME FACTORS;

EID: 69949125186     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.05.020     Document Type: Review

References (123)

1. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., and Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28 (2006) 112-125
2. Allain J.P. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 86 (2004) 83-91
3. Hollinger F.B. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 48 (2008) 1001-1026
4. Biswas R., Tabor E., Hsia C.C., Wright D.J., Laycock M.E., Fiebig E.W., et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 43 (2003) 788-798
5. Scheiblauer H., Soboll H., and Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 78 (2006) S66-S70
6. Matsubara N., Kusano O., Sugamata Y., Itoh T., Mizuii M., Tanaka J., et al. A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection. Transfusion 45 (2009) 585-595
7. Lien T.X., Tien N.T., Chanpong G.F., Cuc C.T., Yen V.T., Soderquist R., et al. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 62 (2000) 301-309
8. Owusu-Ofori S., Temple J., Sarkodie F., Anokwa M., Candotti D., and Allain J.P. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 45 (2005) 133-140
9. Randrianirina F., Carod J.F., Ratsima E., Chrétien J.B., Richard V., and Talarmin A. Evaluation of the performance of four rapid tests for detection of hepatitis B surface antigen in Antananarivo, Madagascar. J Virol Methods 151 (2008) 294-297
10. Allain J.P., Candotti D., Soldan K., Sarkodie F., Phelps B., Giachetti C., et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 101 (2003) 2419-2425
11. Weber B., Dengler T., Berger A., Doerr H.W., and Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. J Clin Microbiol 41 (2003) 135-143
12. Olinger C.M., Weber B., Otegbayo J.A., Ammerlaan W., van der Taelem-Brulé N., and Muller C.P. Hepatitis B virus genotype E surface antigen detection with different immunoassays and diagnostic impact of mutations in the preS/S gene. Med Microbiol Immunol 196 (2007) 247-252
13. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 32 (2005) 102-112
14. Hsu H.-Y., Chang M.-H., Ni Y.-H., and Chen H.-L. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53 (2004) 1499-1503
15. Theamboonlers A., Chongsrisawat V., Jantaradsamee P., and Poovorawan Y. Variants within the "a" determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand's Expanded Program on Immunization (EPI). Tohoku J Exp Med 193 (2001) 197-205
16. Joller-Jemelka H.I., Wicki A.N., and Grob P.J. Detection of HBs antigen in "anti-HBc alone" positive sera. J Hepatol 21 (1994) 269-272
17. Zhang J.M., Xu Y., Wang X.Y., Yin Y.K., Wu X.H., Weng X.H., et al. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis 44 (2007) 1161-1169
18. Kiely P., Stewart Y., and Castro L. Analysis of voluntary blood donors with biologic false reactivity on chemiluminescent immunoassays and implications for donor management. Transfusion 43 (2003) 584-590
19. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009 Feb 27. [Epub ahead of print].
20. Dow B.C., Yates P., Galea G., Munro H., Buchanan I., and Ferguson K. Hepatitis B vaccines may be mistaken for confirmed hepatitis B surface antigen-positive blood donors. Vox Sang 82 (2002) 15-17
21. Davis A.R., Brotchie H.L., Mundkur B.A., and Ismary S.L. Transient hepatitis B surface antigenemia in a blood donor after a combination hepatitis A and B vaccine. Transfusion 43 (2003) 545
22. Roth W.K., and Seifried E. The German experience with NAT. Trans Med 12 (2002) 255-258
23. Kleinman S.H., Kuhns M.C., Todd D.S., Glynn S.A., McNamara A., DiMarco A., et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 43 (2003) 696-704
24. Schifman R.B., Rivers S.L., Sampliner R.E., and Krammes J.E. Significance of isolated hepatitis B core antibody in blood donors. Arch Intern Med 153 (1993) 2261-2266
25. Almeida Neto C., Strauss E., Sabino E.C., Sucupira M.C., and Chamone D.A. Significance of isolated hepatitis B core antibody in blood donors from São Paulo. Rev Inst Med Trop Sao Paulo 43 (2001) 203-208
26. Brojer E., Grabarczyk P., Liszewski G., Mikulska M., Allain J.P., Letowska M., et al. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 44 (2006) 1666-1674
27. Velati C., Romano L., Fomiatti L., Baruffi L., Zanetti A.R., and SIMTI Research Group. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 48 (2008) 2205-2213
28. Margaritis A.R., Brown S.M., Seed C.R., Kiely P., D'Agostino B., and Keller A.J. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion 47 (2007) 1783-1793
29. Nantachit N., Thaikruea L., Thongsawat S., Leetrakool N., Fongsatikul L., Sompan P., et al. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand. Transfusion 47 (2007) 1803-1808
30. Li L., Chen P.J., Chen M.H., Chak K.F., Lin K.S., and Lin Tsai S.J. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 48 (2008) 1198-1206
31. Matsumoto C., Tadokoro K., Fujimura K., Hirakawa S., Mitsunaga S., and Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion 41 (2001) 878-884
32. Sato S., Ohhashi W., Ihara H., Sakaya S., Kato T., and Ikeda H. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion 41 (2001) 1107-1113
33. Yotsuyanagi H., Yasuda K., Moriya K., Shintani Y., Fujie H., Tsutsumi T., et al. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion 41 (2001) 1093-1099
34. Koppelman M.H.G., Sjerps M.C., Reesink H.W., and Cuypers H.T.M. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang 89 (2005) 193-200
35. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49 (2008) 654-659
36. Candotti D., Grabarczyk P., Ghiazza P., Roig R., Casamitjana N., Iudicone P., et al. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 49 (2008) 537-547
37. Marusawa H., Uemoto S., Hijikata M., Ueda Y., Tanaka K., Shimotohno K., et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31 (2000) 488-495
38. Hass M., Hannoun C., Kalinina T., Sommer G., Manegold C., and Gunther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology 42 (2005) 93-103
39. Baginski I., Chemin I., Hantz O., Pichoud C., Jullien A.M., Chevre J.C., et al. Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis. Transfusion 32 (1992) 215-220
40. Manzini P., Abate M.L., Valpreda C., Milanesi P., Curti F., Rizzetto M., et al. Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion 49 (2009) 757-764
41. Yoshikawa A., Gotanda Y., Minegishi K., Taira R., Hino S., Tadokoro K., et al. Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage. Transfusion 47 (2007) 1162-1171
42. Dow B.C., Peterkin M.A., Green R.H.A., and Cameron S.O. Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis B core antigen and HBV DNA. Vox Sang 81 (2001) 140
43. Busch M.P. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?. Trans Clin Biol 11 (2004) 26-32
44. Yugi H., Mizui M., Tanaka J., and Yoshizawa H. Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing - Japanese experience. J Clin Virol 36 (2006) S56-S64
45. Jackson B.R., Busch M.P., Stramer S.L., and AuBuchon J.P. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43 (2003) 721-729
46. Busch M., Walderhaug M., Custer B., Allain J.P., Reddy R., and McDonough B. Risk assessment and cost-effectiveness/utility analysis. Biologicals 37 (2009) 78-87
47. Kuhns M.C., Kleinman S.H., McNamara A.L., Rawal B., Glynn S., and Busch M.P. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 44 (2004) 1332-1339
48. Nardone A., Anastassopoulou C.G., Theeten H., Kriz B., Davidkin I., Thierfelder W., et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 23 (2008) 1-9
49. Ni Y.H., Huang L.M., Chang M.H., Yen C.J., Lu C.Y., You S.L., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 132 (2007) 1287-1293
50. Chang M.W. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. J Clin Virol 36 (2006) S45-S50
51. Pereira J.S.F., Goncales N.S.L., Silva C., Lazarini M.S.K., Pavan M.H.P., Fais V.C., et al. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors. Braz J Med Biol Res 39 (2006) 525-531
52. Singh H., Pradhan M., Singh R.L., Phadke S., Naik S.R., Aggarwal R., et al. High frequency of hepatitis B virus infection in patients with β-thalassemia receiving multiple transfusions. Vox Sang 84 (2003) 292-299
53. Coste J., Reesink H.W., Engelfriet C.P., Laperche S., Brown S., Busch M.P., et al. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 88 (2005) 289-303
54. Kleinman S.H., and Busch M.P. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 36 (2006) S23-S29
55. Busch M.P., Glynn S.A., Stramer S.L., Strong D.M., Caglioti S., Wright D.J., et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 45 (2005) 254-264
56. Van der Bij A.K., Coutinho R.A., and van der Poel C.L. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion 46 (2006) 1729-1736
57. Korelitz J.J., Busch M.P., Kleinman S.H., Williams A.E., Gilcher R.O., Ownby H.E., et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 37 (1997) 634-640
58. Janssen M.P., Cator E.A., van der Poel C.L., Schaasberg W.P., Bonsel G.J., and van Hout B.A. Monitoring viral incidence rates: tools for the implementation of European Union regulations. Vox Sang 96 (2009) 298-308
59. Soldan K., Davison K., and Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill 10 (2005) 17-19
60. Laperche S., Maniez M., Barlet V., El Ghouzzi M.-H., Le Vacon F., Levayer T., et al. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases. Transfusion 48 (2008) 2308-2314
61. Offergeld R., Faensen D., Ritter S., and Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 10 (2005) 8-11
62. Niederhauser C., Schneider P., Fopp M., Ruefer A., and Levy G. Incidence of viral markers and evaluation of the estimated risk in the Swiss blood donor population from 1996 to 2003. Euro Surveill 10 (2005) 14-16
63. O'Brien S., Yi Q.-L., Fan W., Scalia V., Kleinman S.H., and Vamvakas E.C. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 47 (2007) 316-325
64. Dodd R.Y., Notari IV E.P., and Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42 (2002) 975-979
65. Kleinman S.H., Strong D.M., Tegtmeier G.G.E., Holland P.V., Gorlin J.B., Cousins C.R., et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 45 (2005) 1247-1257
66. Seed C.R., Kiely P., and Keller A.J. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 35 (2005) 592-598
67. Tosti M.E., Solinas S., Prati D., Salvaneschi L., Manca M., Francesconi M., et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol 117 (2002) 215-219
68. Alvarez do Barrio M., Gonzalez Diez R., Hernandez Sanchez J.M., and Oyonarte Gomez S. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 10 (2005) 20-22
69. Shang G., Seed C.R., Wang F., Nie D., and Farrugia A. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 47 (2007) 529-539
70. Allain J.P. Estimation of HBV transfusion risk. Transfusion 49 (2009) 1019-1021
71. Schmidt M., Nubling C.M., Scheiblauer H., Chudy M., Walch L.A., Seifried E., et al. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang 91 (2006) 237-243
72. Hennig H., Puchta I., Luhm J., Schlenke P., Goerg S., and Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 100 (2002) 2637-2641
73. Vitale F., Tramuto F., Orlando A., Vizzini G., Meli V., Cerame G., et al. Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection?. J Med Virol 80 (2008) 577-582
74. Chevrier M.C., St-Louis M., Perreault J., Caron B., Castilloux C., Laroche J., et al. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion 47 (2007) 1794-1802
75. O'Brien S.F., Fearon M.A., Yi Q.-L., Fan W., Scalia V., Muntz I.R., et al. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 47 (2007) 1809-1815
76. Hourfar M.K., Jork C., Schottstedt V., Weber-Schehl M., Brixner V., Busch M.P., et al. Experience of German red cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 48 (2008) 1558-1566
77. Stramer S.L. Current risks of transfusion-transmitted agents. Arch Pathol Lab Med 131 (2007) 702-707
78. Ramia S., Ramlawi F., Kanaan M., Klayme S., and Naman R. Frequency and significance of antibodies against hepatitis B core (anti-HBc) antigen as the only serological marker for hepatitis B infection in Lebanese blood donors. Epidemiol Infect 133 (2005) 695-699
79. Katsoulidou A., Moschidis Z., Sypsa V., Chini M., Papatheodoridis G.V., Tassopoulos N.C., et al. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. Vox Sang 92 (2007) 8-14
80. Manzini P., Girotto M., Borsotti R., Giachino O., Guaschino R., Lanteri M., et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 92 (2007) 1664-1670
81. Makroo R.N., Choudhury N., Jagannathan L., Parihar-Malhotra M., Raina V., Chaudhary R.K., et al. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus-1 & hepatitis B & C viruses in Indian blood donors. Indian J Med Res 127 (2008) 140-147
82. Comanor L., and Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 91 (2006) 1-12
83. Liu C.J., Chen D.S., and Chen P.J. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 36 (2006) S33-S44
84. Komiya Y., Katayama K., Yugi H., Mizui M., Matsukura H., Tomoguri T., et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 48 (2008) 286-294
85. Hsia C.C., Purcell R.H., Farshid M., Lachenbruch P.A., and Yu M.Y. Quantification of hepatitis B virus genomes and infectivity in human serum samples. Transfusion 46 (2006) 1829-1835
86. Tsuge M., Hiraga N., Takaishi H., Noguchi C., Oga H., Imamura M., et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42 (2005) 1046-1054
87. Tabuchi A., Tanaka J., Katayama K., Mizui M., Matsukura H., Yugi H., et al. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 80 (2008) 2064-2068
88. Inaba S., Ito A., Miyata Y., Ishii H., Kajimoto S., Tanaka M., et al. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 46 (2006) 2028-2029
89. Satake M., Taira R., Yugi H., Hino S., Kanemitsu K., Ikeda H., et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 47 (2007) 1197-1205
90. Wang J.T., Lee C.Z., Chen P.J., Wang T.H., and Chen D.S. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 42 (2002) 1592-1597
91. Hoofnagle J.H., and Waggoner J.G. Hepatitis A and B virus markers in immune serum globulin. Gastroenterology 78 (1980) 259-263
92. Stramer S.L. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Transfusion 45 (2005) 1242-1246
93. Soldan K., Barbara J.A.J., and Dow B.C. Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target. Vox Sang 83 (2002) 305-308
94. Jongerius J.M., van der Poel C.L., and van Leeuwen E.F. A simple strategy to look back on posttransfusion hepatitis B in a multitransfused patient. Vox Sang 75 (1998) 66-69
95. Dreier J., Kroger M., Diekmann J., Gotting C., and Kleesiek K. Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med 14 (2004) 97-103
96. Gerlich W.H. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol 36 (2006) S18-S22
97. Levicnik-Stezinar S., Rahne-Potokar U., Candotti D., Lelie N., and Allain J.P. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 48 (2008) 1022-1025
98. Wendel S., Levi J.E., Biagini S., Candotti D., and Allain J.-P. A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period. Transfusion 48 (2008) 1602-1608
99. Chudy M., Schmidt M., Czudai V., Scheiblauer H., Nick S., Mosebach M., et al. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 44 (2006) 99-107
100. Gerlich W.H., Wagner F.F., Chudy M., Holm Harritshoj L., Lattermann A., Wienzek S., et al. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 79 (2007) S32-S36
101. Prince A.M., Lee D.H., and Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 41 (2001) 329-332
102. Barcena R., Moraleda G., Moreno J., Martin M.D., de Vicente E., Nuno J., et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 12 (2006) 2070-2074
103. Dodson S.F. Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors. Clin Transplant 14 (2000) S20-S24
104. Roque-Afonso A.M., Feray C., Samuel D., Simoneau D., Roche B., Emile J.F., et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 50 (2002) 95-99
105. Roche B., Feray C., Gigou M., Roque-Afonso A.M., Arulnaden J.L., Delvart V., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 38 (2003) 86-95
106. Grob P., Jilg W., Bornhak H., Gerken G., Gerlich W., Günther S., et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 62 (2000) 450-455
107. Allain J.P., Hewitt P.E., Tedder R.S., and Williamson L. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 107 (1999) 186-195
108. Mosley J.W., Stevens C.E., Aach R.D., Hollinger F.B., Mimms L.T., Solomon L.R., et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 35 (1995) 5-12
109. Liu C.J., Lo S.H., Kao J.H., Tseng P.T., Lai M.Y., Ni Y.H., et al. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 44 (2006) 39-46
110. Knoll A., Boehm S., Hahn J., Holler E., and Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 14 (2007) 478-483
111. Su F.H., Chen J.D., Cheng S.H., Sung K.Y., Jeng J.J., and Chu F.Y. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat 15 (2008) 14-19
112. Van Damme P., and Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5 (2007) 79-84
113. Roche B., Samuel D., Gigou M., Feray C., Virot V., Schmets L., et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 26 (1997) 517-526
114. Dickson R.C., Wright R.M., Bacchetta M.D., Bodily S.E., Caldwell S.H., Driscoll C.J., et al. Quality of life of hepatitis B and C patients after liver transplantation. Clin Transplant 11 (1997) 282-285
115. Uemoto S., Sugiyama K., Marusawa H., Inomata Y., Asonuma K., Egawa H., et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65 (1998) 494-499
116. Kim K.H., Ahn S.H., Chung H.Y., Paik Y.H., Lee K.S., Kim Y.S., et al. Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol 19 (2004) 847-853
117. Llewelyn C.A., Wells A.W., Amin M., Casbard A., Johnson A.J., Ballard S., et al. The EASTR study: a new approach to determine the reasons for transfusion in epidemiological studies. Transfus Med 19 (2009) 89-98
118. Hollinger F.B., and Dodd R.Y. Hepatitis B virus traceback and lookback: factors to consider. Transfusion 49 (2009) 176-184
119. Allain J.P., Belkhiri D., Vermeulen M., Crookes R., Cable R., Amiri A., et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 49 (2009) 1868-1876
120. Franklin I.M., Dow B.C., and Jordan A.D. Benefits of a blood donation archive repository: international survey of donor repository procedures and Scottish experiences. Transfusion 47 (2007) 1172-1179
121. Allain J.P. Occult hepatitis B virus infection and transfusion. J Hepatol 44 (2006) 618-619
122. Prati D., Gerosa A., and Porretti L. Occult HBV infection and blood transfusion. J Hepatol 44 (2006) 818
123. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113 (2009) 3147-3153